September 4, 2019
Nanobiotix Announces Half-year Financial Statements as of June 30, 2019
Major milestone achieved in the form of first European market approval (CE Marking) for Hensify® (NBTXR3) in locally advanced Soft…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
September 4, 2019
The Chinese Human Vaccine Industry: 2019-2025 Analysis & Outlook Report – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “China Human Vaccine Industry Report, 2019-2025” report has been added to ResearchAndMarkets.com’s offering. The report highlights the following:…
September 4, 2019
Novitium gets Orfadin generic equicalent approval from USFDA
Novitium Pharma, LLC, a partner of Endo’s subsidiary Endo Ventures Limited, received approval from the U.S. Food and Drug Administration for a room temperature stable, AB-rated, generic equivalent of Swedish Orphan Biovitrum’s Orfadin.
September 4, 2019
VenatoRx Pharmaceuticals Names Joseph C. Larsen, Ph.D. Vice President, Strategic Portfolio Development
VenatoRx Pharmaceuticals today announced that Joseph C. Larsen, Ph.D. has joined the Company as Vice President, Strategic Portfolio Development. With more than 20 years’ experience, Dr. Larsen is globally recognized as a leader in the area of public health preparedness. At VenatoRx, Dr. Larsen will help translate VenatoRx’s rich internal programs toward strategic public and private partnerships, and will help identify new growth opportunities for VenatoRx.
September 4, 2019
European Commission Approves Expanded Use of Janssen’s STELARA for the Treatment of Moderately to Severely Active Ulcerative Colitis in the European Union
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has approved the expanded use of ustekinumab for the treatment of adults with moderately to severely active ulcerative colitis (UC), who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.
September 4, 2019
Beam Therapeutics Appoints Financial Industry Veteran, Terry-Ann Burrell, as Chief Financial Officer
Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of financial industry veteran, Terry-Ann Burrell, as chief financial officer. Ms. Burrell joins Beam from J.P. Morgan, where she was a managing director in the healthcare investment banking group.
September 4, 2019
CTD Holdings Interview to Air on Bloomberg International on the RedChip Money Report
ALACHUA, Fla.–(BUSINESS WIRE)–CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biopharmaceutical company that develops cyclodextrin-based products for the treatment of…
September 4, 2019
CTD Holdings Interview to Air on Bloomberg International on the RedChip Money Report
ALACHUA, Fla.–(BUSINESS WIRE)–CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biopharmaceutical company that develops cyclodextrin-based products for the treatment of…
September 4, 2019
MedinCell Receives a New Grant to Develop a Best-in-class Long-acting Injectable Product for HIV PrEP
MedinCell receives a grant from The Bill & Melinda Gates Foundation for a product aimed at preventing HIV infection. This…
September 4, 2019
MedinCell Receives a New Grant to Develop a Best-in-class Long-acting Injectable Product for HIV PrEP
MedinCell receives a grant from The Bill & Melinda Gates Foundation for a product aimed at preventing HIV infection. This…